Proposal for BAM15 (Sigma-Aldrich, Cat. #SML0763)

Overview of Therapeutic Candidate:
BAM15 is a synthetic mitochondrial protonophore that was originally discovered through high‐throughput chemical screening designed to identify compounds that could safely increase mitochondrial oxygen consumption without the deleterious off‐target effects typically observed with classical uncouplers such as 2,4-dinitrophenol (DNP) or FCCP (Alexopoulos, 2023; Kenwood et al., 2014). Chemically, BAM15 belongs to a novel class of oxadiazolo-pyrazine derivatives that exhibit protonophoric activity by selectively targeting the mitochondrial inner membrane, thereby facilitating proton leak and uncoupling oxidative phosphorylation from ATP synthesis (Alexopoulos, 2023; Kenwood & Hoehn, 2014). Unlike earlier mitochondrial uncouplers, BAM15 has been engineered to demonstrate a broad effective dosing window, high mitochondrial specificity, and a reduced propensity to depolarize the plasma membrane, which has historically limited the therapeutic application of uncouplers due to toxicity concerns (Kenwood et al., 2014; Shrestha et al., 2021). The compound is commercially available from suppliers such as Sigma-Aldrich (Cat. #SML0763) and is currently being repurposed from its research applications into potential therapeutic use for metabolic disorders, most notably non-alcoholic steatohepatitis (NASH), due to its ability to enhance cellular fatty acid oxidation and improve mitochondrial function (ClinicalTrials.gov, n.d.).

Therapeutic History:
BAM15 has primarily been investigated in preclinical settings with a focus on mitochondrial bioenergetics and metabolic modulation. Recent studies using rodent models of diet-induced obesity and NASH have shown that BAM15 administration leads to improved mitochondrial respiratory capacity, increased energy expenditure, and reductions in hepatic triglyceride content (Alexopoulos, 2023). In these studies, BAM15 not only promoted fat loss but also improved insulin sensitivity and reversed hyperinsulinemia in animals fed obesogenic diets, suggesting its utility in metabolic conditions that share pathophysiological features with NASH (Alexopoulos, 2023; Xiong et al., 2023). While BAM15’s historical record in clinical practice remains that of an investigational drug—its use has been confined to research laboratories and preclinical studies—it stands apart from classical mitochondrial uncouplers like DNP, which were previously investigated for obesity but ultimately discontinued due to a narrow therapeutic window and safety liabilities (Alexopoulos, 2023; Kenwood et al., 2014). The extensive preclinical data to date, including robust pharmacokinetic profiles indicating oral bioavailability (approximately 67%) and a moderate half-life (approximately 1.7 hours in mice), further support the potential repurposing of BAM15 for therapeutic intervention in NASH, a disease highly characterized by mitochondrial dysfunction, impaired fatty acid oxidation, and hepatic lipid overload (Alexopoulos, 2023; Boeira et al., 2023).

Mechanism of Action:
BAM15 exerts its pharmacological effects via a well-characterized mechanism of mitochondrial uncoupling. At the molecular level, BAM15 functions as a protonophore; it facilitates the translocation of protons (H⁺) across the mitochondrial inner membrane independent of ATP synthase activity, resulting in a dissipation of the proton motive force that is otherwise coupled to ATP production (Alexopoulos, 2023; Xiong et al., 2023). This controlled uncoupling leads to increased oxygen consumption and substrate oxidation as mitochondria compensate for the loss of coupling efficiency, thereby enhancing fatty acid β-oxidation—a key metabolic process impaired in NASH (Alexopoulos, 2023; Axelrod et al., 2020). Importantly, BAM15’s action is selective for mitochondria due to its lipophilic nature and higher pKa, which restricts its activity to the mitochondrial environment and prevents deleterious plasma membrane depolarization typically seen with other uncoupling agents (Kenwood et al., 2014; Shrestha et al., 2021). Additionally, BAM15 has been shown to activate AMP-activated protein kinase (AMPK), a master regulator of energy metabolism that enhances glucose uptake and fatty acid oxidation while suppressing de novo lipogenesis (Axelrod et al., 2020; Dang et al., 2021). The compound also exhibits anti-inflammatory properties, possibly by modulating reactive oxygen species (ROS) production and restraining inflammatory cytokine release, which is beneficial in the context of NASH where chronic inflammation contributes to disease progression (Xiong et al., 2023; Dang et al., 2021). Collectively, these molecular interactions indicate that BAM15 improves hepatocellular metabolism by boosting substrate oxidation via increased mitochondrial respiration, reducing the accumulation of lipotoxic species in the liver without inducing systemic hyperthermia (Alexopoulos, 2023; Kenwood & Hoehn, 2014).

Expected Effect:
In the context of Non-alcoholic Steatohepatitis, BAM15 is hypothesized to achieve beneficial effects by subtly uncoupling oxidative phosphorylation in hepatocytes. This mild uncoupling is expected to boost the rate of substrate oxidation and, in particular, enhance fatty acid β-oxidation, thereby reducing hepatic lipid overload—a central pathological feature of NASH (Alexopoulos, 2023; Xiong et al., 2023). Experimental data from rodent models have already demonstrated that BAM15 administration results in significant reductions in liver triglycerides and improvements in insulin sensitivity; these metabolic benefits directly translate to an amelioration of NASH-related liver pathology, as evidenced by improved histological scores such as the NAFLD Activity Score (NAS) and reduced levels of plasma alanine aminotransferase (ALT) (Alexopoulos, 2023). The expected outcome in hepatocyte assays is an increase in the oxygen consumption rate (OCR) and a decrease in mitochondrial membrane potential, indicating effective uncoupling and increased fatty acid oxidation, as measured, for instance, by Seahorse respirometry assays (Alexopoulos, 2023; Xiong et al., 2023). Moreover, since the AMP-activated protein kinase (AMPK) pathway is known to be upregulated in response to energy stress such as that induced by mitochondrial uncoupling, further activation of AMPK is anticipated; this would serve to enhance glucose uptake and suppress lipogenic gene expression in hepatocytes, contributing to the overall metabolic improvement observed in preclinical studies (Axelrod et al., 2020; Dang et al., 2021). Additional supportive evidence from studies evaluating mitochondrial uncouplers in similar settings, including experiments in isolated hepatocytes and in vivo rodent models, reinforces the notion that BAM15 will reduce ectopic fat accumulation, alleviate oxidative stress, and exert anti-inflammatory effects via its modulation of mitochondrial respiration (Alexopoulos, 2023; Xiong et al., 2023).

Overall Evaluation:
Based on the comprehensive literature review, BAM15 emerges as a highly promising therapeutic candidate for the treatment of Non-alcoholic Steatohepatitis. Its origins as a synthetically derived mitochondrial uncoupler that has been rationally designed to overcome the safety liabilities of traditional uncoupling agents (e.g., DNP and FCCP) provide a strong foundation for targeted metabolic modulation (Kenwood et al., 2014; Alexopoulos, 2023). One of the primary strengths of BAM15 is its mechanism of action; by subtly uncoupling oxidative phosphorylation, it increases mitochondrial substrate oxidation and fatty acid β-oxidation in hepatocytes without inducing hyperthermia or significant cytotoxicity—a major limitation of many earlier compounds in this class (Xiong et al., 2023; Axelrod et al., 2020). The activation of AMPK further supports its favorable metabolic profile, as AMPK acts as an energy sensor that encourages catabolic processes and reduces lipogenesis, ultimately contributing to a reduction in hepatic lipid accumulation and an improvement in overall metabolic homeostasis (Axelrod et al., 2020; Dang et al., 2021). Preclinical data in rodents, including improved insulin sensitivity, decreased liver triglyceride content, and favorable histopathological changes in diet-induced NASH models, provide compelling evidence of its therapeutic potential (Alexopoulos, 2023).

However, some challenges remain that could impact the clinical translation of BAM15. Its poor aqueous solubility limits formulation options and may require innovative delivery approaches—such as dietary admixture or nanoparticle encapsulation—to achieve consistent systemic exposure (Alexopoulos, 2023; Xiong et al., 2023). Additionally, although rodent pharmacokinetic profiles are encouraging with acceptable bioavailability and a moderate half-life, further investigation in higher-order preclinical models and eventual human studies will be necessary to fully assess long-term safety and efficacy, as well as potential off-target effects that might not be captured in short-term studies (Alexopoulos, 2023; Kenwood & Hoehn, 2014). The mechanistic specificity of BAM15 as demonstrated by its minimal plasma membrane depolarization and favorable mitochondrial targeting represents a significant advancement; yet, given the complex pathogenesis of NASH—where inflammation, lipotoxicity, and fibrogenesis intersect—the therapeutic efficacy of BAM15 may need to be validated as part of combination regimens rather than as a standalone treatment (Kenwood et al., 2014; Alexopoulos, 2023).

In summary, BAM15’s strengths lie in its well-defined molecular mechanism, enhanced mitochondrial specificity, safety profile in preclinical rodent models, and its ability to effectively modulate key metabolic pathways implicated in NASH pathology. Its potential to reduce hepatic lipid accumulation and improve insulin sensitivity while avoiding the hyperthermic and cytotoxic side effects associated with older mitochondrial uncouplers makes it a compelling candidate for further development (Alexopoulos, 2023; Xiong et al., 2023). The primary weaknesses are related to formulation challenges due to low aqueous solubility and the need for extensive further studies to confirm long-term safety and efficacy in human-relevant models (Alexopoulos, 2023; Kenwood & Hoehn, 2014). Overall, the evidence supports pursuing additional preclinical development of BAM15, with particular emphasis on optimizing its pharmacokinetic properties and establishing robust efficacy endpoints in suitable NASH models before moving toward clinical trials (ClinicalTrials.gov, n.d.).

References
Alexopoulos, S. J. (2023). Assessing the therapeutic potential of mitochondrial uncoupler bam15. Unknown Journal.
Axelrod, C. L., King, W. T., Davuluri, G., Noland, R. C., Hall, J., Hull, M., Dantas, W. S., Zunica, E. R. M., Alexopoulos, S. J., Hoehn, K. L., Langohr, I., Stadler, K., Doyle, H., Schmidt, E., Nieuwoudt, S., Fitzgerald, K., Pergola, K., Fujioka, H., Mey, J. T., Fealy, C., Mulya, A., Beyl, R., Hoppel, C. L., & Kirwan, J. P. (2020). Bam15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202012088
Boeira, P., Affourtit, C., Felmlee, D., & Sheridan, D. (2023). Investigation of microbiome metabolites and mitochondrial function in non-alcoholic fatty liver disease. Journal of Hepatology, 73, S240. https://doi.org/10.1016/S0168-8278(20)30983-1
ClinicalTrials.gov. (n.d.). Search for BAM15 OR mitochondrial uncoupler OR protonophore OR BAM15 SML0763 OR mitochondrial uncoupler AND non-alcoholic steatohepatitis OR fatty liver. ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov
Dang, C. P., Issara-Amphorn, J., Charoensappakit, A., Udompornpitak, K., Bhunyakarnjanarat, T., Saisorn, W., Sae-Khow, K., & Leelahavanichkul, A. (2021). Bam15, a mitochondrial uncoupling agent, attenuates inflammation in the LPS injection mouse model: An adjunctive anti-inflammation on macrophages and hepatocytes. Journal of Innate Immunity, 13, 359–375. https://doi.org/10.1159/000516348
Kenwood, B. M., & Hoehn, K. L. (2014). Identification and design of a novel family of mitochondrial protonophores for bioenergetics analysis and the treatment of ischemia-reperfusion injury (Doctoral dissertation). University of Virginia. https://doi.org/10.18130/v31n9k
Kenwood, B. M., Weaver, J. L., Bajwa, A., Poon, I. K., Byrne, F. L., Murrow, B. A., Calderone, J. A., Huang, L., Divakaruni, A. S., Tomsig, J. L., Okabe, K., Lo, R. H., Coleman, G. C., Columbus, L., Yan, Z., Saucerman, J. J., Smith, J. S., Holmes, J. W., Lynch, K. R., Ravichandran, K. S., Uchiyama, S., Santos, W. L., Rogers, G. W., Okusa, M. D., Bayliss, D. A., & Hoehn, K. L. (2014). Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane. Molecular Metabolism, 3, 114–123. https://doi.org/10.1016/j.molmet.2013.11.005
Shrestha, R., Johnson, E., & Byrne, F. L. (2021). Exploring the therapeutic potential of mitochondrial uncouplers in cancer. Molecular Metabolism, 51, 101222. https://doi.org/10.1016/j.molmet.2021.101222
Xiong, G., Zhang, K., Ma, Y., Song, Y., Zhang, W., Qi, T., Qiu, H., Shi, J., Kan, C., Zhang, J., & Sun, X. (2023). Bam15 as a mitochondrial uncoupler: A promising therapeutic agent for diverse diseases. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2023.1252141
